Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.
"As a successful start to the new year, we were able to complete this very important project for CHEPLAPHARM, which perfectly complements our portfolio of globally marketed benzodiazepines. We are proud to build on a long-standing relationship with Roche," says CEO Sebastian F. Braun, “and are pleased with the acquisition of the established brand among patients and prescribers.”
Rivotril® is a branded prescription drug which is commonly used and indicated in the therapeutic area of eplilepsy and panic disorder. This benzodiazepine with the active ingredient clonazepam is a well-established, globally marketed product. Rivotril® was launched in 1973 and is currently registered in approximately 85 countries.